Common cancers associated with the PRMT5 include lymphoma via the activation of the WNT/beta-catenin pathway, leukemia via suppression RB, DLBCL via upregulation of the BCR-BKT- NF-kB signaling, AML via regulation of alternative splicing by SRSF1 methylation, colorectal cancer via methylation of the BX1, Glioblastoma via the splicing of the ST7 tumor suppressor gene and bladder cancer via the enhancement of NF-kB activation [14]. This evidence concerns the gene NFKB1 and urinary bladder carcinoma.